Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities-Reference-Cited by-同舟云学术

Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities

Published:2024-04-06 Issue:5 Volume:10 Page:1679-1695
ISSN:2373-8227
Container-title:ACS Infectious Diseases
language:en
Short-container-title:ACS Infect. Dis.

Author:

Boshoff Helena I. M.¹^ORCID,Young Katherine²,Ahn Yong-Mo¹,Yadav Veena D.¹,Crowley Brendan M.²,Yang Lihu²,Su Jing²,Oh Sangmi¹^ORCID,Arora Kriti¹,Andrews Jenna¹,Manikkam Michelle³,Sutphin Michelle³,Smith Anthony J.⁴,Weiner Danielle M.³,Piazza Michaela K.³,Fleegle Joel D.³,Gomez Felipe³,Dayao Emmannual K.³,Prideaux Brendan²,Zimmerman Matthew⁵,Kaya Firat⁵^ORCID,Sarathy Jansy⁵,Tan Vee Yang¹,Via Laura E.³,Tschirret-Guth Richard²,Lenaerts Anne J.⁴,Robertson Gregory T.⁴,Dartois Véronique⁴^ORCID,Olsen David B.²,Barry Clifton E¹^ORCID

Affiliation:

1. Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, Maryland 20892, United States

2. Merck & Co., Inc., West Point, Pennsylvania 19486, United States

3. Tuberculosis Imaging Program, Division of Intramural Research, National Insititute of Allergy and Infectious Disease, National Insititutes of Health, Bethesda, Maryland 20892, United States

4. Mycobacterial Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Ft Collins, Colorado 80521, United States

5. Hackensack Meridian Health Center for Discovery & Innovation, Nutley, New Jersey 07110, United States

Funder

Division of Intramural Research

Bill and Melinda Gates Foundation

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.4c00025

Reference39 articles.

1. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis

2. Linezolid for XDR-TB — Final Study Outcomes

3. Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis

4. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis

5. Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents against Drug-Resistant Pathogens;Journal of Medicinal Chemistry;2024-09-05